Epineuron Announces Topline Pilot Study Results Published in Bioelectronic Medicine Showing the Potential of the PeriPulse® System in Accelerating Nerve Regeneration

Audio By Carbonatix

TORONTO--(BUSINESS WIRE)--May 7, 2025--

A groundbreaking first-in-human trial has revealed the potential of the PeriPulse® Nerve Stimulation System, a wearable temporary nerve stimulator, in enabling electrical stimulation therapy for the regeneration of acutely injured peripheral nerves. In a study published in Bioelectronic Medicine, results showed a significant and sustained improvement in sensation, with 87.5% of treated patients demonstrating clinically meaningful gains 6 months after injury compared to pre-surgery. This highlights the potential of electrical stimulation therapy to drive substantial functional recovery.

Treating peripheral nerve injuries remains challenging, particularly in acute trauma scenarios. Surgery, the current standard of care, often results in slow and incomplete recovery, creating substantial burdens for patients and healthcare systems. Epineuron's novel PeriPulse® system provides a simple workflow to improve patient outcomes without prolonging operating room time. “This publication is an important milestone for Epineuron and a testament to our vision for the future of improving nerve regeneration. The utility of our efficient approach to deploying therapy was validated and we look forward to helping patients recover following nerve surgery,” said Dr. Mike Willand, PhD, Co-Founder and CTO at Epineuron.

The system demonstrated a high degree of patient tolerance and safety, underscoring its potential for widespread adoption. The findings offer new hope for patients and provides surgeons the prospect of delivering needed treatment. The study results have paved the way for REGAIN™, the largest multinational medical device trial for nerve regeneration, currently underway across Canada and the US, which is designed to support the company’s FDA approval.

"Better nerve regeneration is game changing for patients," said Dr. James Bain, MD, MSc, Professor of Plastic Surgery, McMaster University and corresponding author of the study. "The novel system provides a simple and effective way to deliver electrical stimulation therapy that does not impact my workflow and prolong my surgeries. This system and approach have the potential to significantly improve outcomes for patients with peripheral nerve injuries.”

About Epineuron

Epineuron is a nerve care company dedicated to advancing bioelectronic solutions for the repair and treatment of damaged nerves. Its flagship technology, PeriPulse®, is Health Canada approved and designated an FDA Breakthrough Device. It uses electrical stimulation to accelerate the recovery of injured peripheral nerves with a seamless perioperative workflow.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250506255649/en/

CONTACT: Dr. Mike Willand, PhD, PEng

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CANADA

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES NEUROLOGY SURGERY HEALTH TECHNOLOGY GENERAL HEALTH CLINICAL TRIALS

SOURCE: Epineuron

Copyright Business Wire 2025.

PUB: 05/07/2025 10:30 AM/DISC: 05/07/2025 10:29 AM

http://www.businesswire.com/news/home/20250506255649/en